Prostate cancer, malignant (ICD10 C61): men
Five-year relative survival by diagnosis year and age at diagnosis
|
Five-year relative survival (with 95% confidence interval) by diagnosis year |
EUROCARE-4 |
EUROCARE-4 |
||||||||||
|
Age at diagnosis |
1994-97 |
1998-2002 |
2003-2007 |
2007-2009 |
##2000-2002 |
##2000-2002 |
||||||
|
cohort |
cohort |
cohort |
*hybrid |
Ireland |
Europe average |
|||||||
|
all 15-99 |
65.0% |
80.7% |
92.8% |
93.2% |
||||||||
|
(unstandardized) |
(62.8-67.1%) |
(79.2-82.0%) |
(91.5-94.0%) |
(91.9-94.4%) |
||||||||
|
all 15-99 |
65.2% |
80.5% |
89.9% |
90.4% |
- |
77.5% |
||||||
|
(age-standardized)# |
(59.6-70.4%) |
(77.2-83.5%) |
(86.7-92.8%) |
(87.3-93.3%) |
[sparse data] |
(76.5-78.6%) |
||||||
|
15-44 |
65.2% |
86.8% |
95.5% |
97.3% |
||||||||
|
(54.7-74.0%) |
(82.2-90.4%) |
(93.3-97.2%) |
(94.7-99.0%) |
|||||||||
|
45-54 |
70.9% |
89.2% |
96.8% |
96.9% |
||||||||
|
(66.4-74.9%) |
(87.1-91.1%) |
(95.3-98.1%) |
(95.5-98.2%) |
|||||||||
|
55-64 |
65.6% |
83.4% |
93.1% |
92.8% |
||||||||
|
(62.5-68.5%) |
(81.3-85.2%) |
(91.2-94.9%) |
(90.9-94.5%) |
|||||||||
|
65-74 |
62.2% |
68.0% |
82.4% |
83.1% |
||||||||
|
(58.0-66.3%) |
(64.6-71.2%) |
(78.1-86.5%) |
(79.0-87.0%) |
|||||||||
|
75-99 |
53.5% |
61.2% |
57.9% |
60.4% |
||||||||
|
(41.3-67.0%) |
(51.1-72.0%) |
(45.2-71.7%) |
(47.7-74.2%) |
|||||||||
|
Footnotes: |
|
|
*Hybrid estimate for 2007-2009 is the most up-to-date survival estimate and is based on follow-up of all cases alive at any point during this period, |
|
|
supplemented by follow-up 2005-2009 for cases diagnosed in 2005 or 2006 (to provide more reliable estimation of the first two years of survival). |
|
|
In practice, the hybrid estimate for 2007-2009 is similar to the most recent (incomplete) cohort, i.e. cases diagnosed 2003-2007, reflecting substantial overlap of data. |
|
|
# Age-standardized figures use the standard patient population proposed for this cancer by: |
|
|
Corazziari I., Quinn M. & Capocaccia R. 2004. Standard cancer patient population for age standardising survival ratios. Eur J Cancer 40: 2307-2316. |
|
|
(Population weights = age 15-54 x19000, 55-64 x23000, 65-74 x29000, 75-84 x239000, 85-99 x6000; note age-ranges used for this cancer differ from most other cancers) |
|
|
## For comparison, the age-standardized average survival (2000-2002) is quoted for countries (including Ireland) that participated in the EUROCARE-4 study: |
|
|
Verdecchia A., Francisci S., Brenner H., et al. 2007. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 8: 784-796. |
|
|
Exclusions (as in EUROCARE): |
|
|
Patients aged <15 or >99 at diagnosis; death-certificate-only (DCO) and autopsy-only cases; second or subsequent malignancies in the same patient |
|
|
(or the less serious of two or more synchronously-diagnosed malignancies); in situ carcinomas and tumours of uncertain behaviour. |
|
|
© National Cancer Registry Ireland 2011 (October 2011) Relative survival statistics for Irish cancer patients |
|